Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Obesity on Presentation of Breast Cancer, Lymph Node Metastasis and Patient Survival: A Retrospective Review

  • Published : 2013.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: As data on the relation between obesity and lymph node ratio are missing in the literature, we here aimed to assess the impact of obesity on this parameter and other clinicopathological features of breast cancer cases and patient survival. Materials and Methods: Medical data of 646 patients, all referred to two centers in Tehran, Iran, were reviewed. Factors that showed significant association on univariate analysis were entered in a regression model. Kaplan-Meier and Cox-regression were employed for survival analysis. Results: Obesity was correlated with the expression of estrogen and progesterone receptor (p=0.004 and p=0.039, respectively), metastasis to axillary lymph nodes (p=0.017), higher lymph node rate (p<0.001) and larger tumor size (p<0.001). The effect of obesity was stronger in premenopausal women. There was no association between obesity and expression of human epidermal growth factor receptor. Three factors showed independent association with BMI on multivariate analysis; tumor size, estrogen receptor and lymph node ratio. Obesity was predictive of shorter disease-free survival with a hazard ratio of 3.324 (95%CI: 1.225-9.017) after controlling for the above-mentioned variables. Conclusions: The findings of this study support the idea that obese women experience more advanced disease with higher axillary lymph node ratio, and therefore higher stage at the time of diagnosis. Furthermore, obesity was associated with poorer survival independent of lymph node rate.

Keywords

References

  1. Andrieu N, Goldgar DE, Easton DF, et al (2006). Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst, 98, 535-44. https://doi.org/10.1093/jnci/djj132
  2. Bachelot T, Ray-Coquard I, Menetrier-Caux C, et al (2003). Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer, 88, 1721-6. https://doi.org/10.1038/sj.bjc.6600956
  3. Berclaz G, Li S, Price KN, et al (2004). Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol, 15, 875-84 https://doi.org/10.1093/annonc/mdh222
  4. Chlebowski RT, Aiello E, McTiernan A (2002). Weight Loss in Breast Cancer Patient Management. J Clin Oncol, 20, 1128-43. https://doi.org/10.1200/JCO.20.4.1128
  5. Cui Y, Whiteman MK, Flaws JA, et al (2002). Body mass and stage of breast cancer at diagnosis. Int J Cancer, 98, 279-83. https://doi.org/10.1002/ijc.10209
  6. Daling JR, Malone KE, Doody DR, et al (2001). Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer, 92, 720-9. https://doi.org/10.1002/1097-0142(20010815)92:4<720::AID-CNCR1375>3.0.CO;2-T
  7. Deglise C, Bouchardy C, Burri M, et al (2010). Impact of obesity on diagnosis and treatment of breast cancer. Breast Cancer Res Treat, 120, 185-93. https://doi.org/10.1007/s10549-009-0459-1
  8. Enger SM, Ross RK, Paganini-Hill A, et al (2000). Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies. Cancer Epidemiol Biomarkers Pre, 9, 681-7.
  9. Esfahlan RJ, Zarghami N, Esfahlan AJ, et al (2011). The possible impact of obesity on androgen, progesterone and estrogen receptors (ERalpha and ERbeta) gene expression in breast cancer patients. Breast Cancer (Auckl), 5, 227-37.
  10. Ewertz M, Jensen MB, Gunnarsdottir KA, et al (2011). Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol, 29, 25-31. https://doi.org/10.1200/JCO.2010.29.7614
  11. Gillespie E, Sorbero M, Hanauer D, et al (2010). Obesity and angiolymphatic invasion in primary breast cancer. Ann Surg Oncol, 17, 752-9. https://doi.org/10.1245/s10434-009-0797-6
  12. Griggs JJ, Sorbero MES, Lyman GH (2005). Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med, 165, 1267-73. https://doi.org/10.1001/archinte.165.11.1267
  13. Han W, Kim S, Park IA, et al (2004). Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer, 4, 82. https://doi.org/10.1186/1471-2407-4-82
  14. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  15. Jernstrom H, Lubinski J, Lynch HT, et al (2004). Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst, 96, 1094-8. https://doi.org/10.1093/jnci/djh211
  16. Jordan I, Hebestreit A, Swai B, Krawinkel MB (2010). Breast cancer risk among women with long-standing lactation and reproductive parameters at low risk level: a case-control study in Northern Tanzania. Breast Cancer Res Treat, [Epub ahead of print].
  17. Key TJ, Verkasalo PK, Banks E (2001). Epidemiology of breast cancer. Lancet Oncol, 2, 133-40. https://doi.org/10.1016/S1470-2045(00)00254-0
  18. Li CI, Daling JR, Porter PL, et al (2009). Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. J Clin Oncol, 27, 5312-8. https://doi.org/10.1200/JCO.2009.23.1597
  19. Maiti B, Kundranda M, Spiro T, Daw H (2010). The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Res Treat, 121, 479-83. https://doi.org/10.1007/s10549-009-0591-y
  20. Morris PG, Hudis CA, Giri D, et al (2011). Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res, 4, 1021-9. https://doi.org/10.1158/1940-6207.CAPR-11-0110
  21. Olefsky JM, Glass CK (2010). Macrophages, inflammation, and insulin resistance. Annu Rev Physiol, 72, 219-46. https://doi.org/10.1146/annurev-physiol-021909-135846
  22. Ove Mæhle B, Tretli S, Skjærven R, Thorsen T (2001). Premorbid body weight and its relations to primary tumour diameter in breast cancer patients; its dependence on estrogen and progesteron receptor status. Breast Cancer Res Treat, 68, 159-69. https://doi.org/10.1023/A:1011977118921
  23. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global Cancer Statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  24. Porter G, Inglis K, Wood L, Veugelers P (2006). Effect of obesity on presentation of breast cancer. Ann Surg Oncol, 13, 327-32. https://doi.org/10.1245/ASO.2006.03.049
  25. Protani M, Coory M, Martin J (2010). Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat, 123, 627-35. https://doi.org/10.1007/s10549-010-0990-0
  26. Ritte R, Lukanova A, Tjonneland A, et al (2013). Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: a cohort study. Int J Cancer, 132, 2619-29. https://doi.org/10.1002/ijc.27913
  27. Rock CL, Demark-Wahnefried W (2002). Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol, 20, 3302-16. https://doi.org/10.1200/JCO.2002.03.008
  28. Singh AK, Pandey A, Tewari M, et al (2011). Obesity augmented breast cancer risk: a potential risk factor for Indian women. J Surg Oncol, 103, 217-22. https://doi.org/10.1002/jso.21768
  29. Singletary SE, Allred C, Ashley P, et al (2002). Revision of the American Joint Committee on cancer staging system for breast cancer. J Clin Oncol, 20, 3628-36. https://doi.org/10.1200/JCO.2002.02.026
  30. Stuebe AM, Willett WC, Xue F, Michels KB (2009). Lactation and incidence of premenopausal breast cancer: a longitudinal study. Arch Intern Med, 169, 1364-71. https://doi.org/10.1001/archinternmed.2009.231
  31. Van der Wal B, Butzelaar R, Van Der Meij S, Boermeester M (2002). Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol, 28, 481-9. https://doi.org/10.1053/ejso.2002.1239
  32. Van Leeuwen FE, Rookus MA (2003). Breast cancer and hormone-replacement therapy: the million women study. Lancet, 362, 1330. https://doi.org/10.1016/S0140-6736(03)14596-5
  33. Vinh-Hung V, Verkooijen HM, Fioretta G, et al (2009). Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol, 27, 1062-8. https://doi.org/10.1200/JCO.2008.18.6965
  34. Wee CC, McCarthy EP, Davis RB, Phillips RS (2004). Obesity and breast cancer screening. J Gen Intern Med, 19, 324-31. https://doi.org/10.1111/j.1525-1497.2004.30354.x
  35. Weiss LK, Burkman RT, Cushing-Haugen KL, et al (2002). Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol, 100, 1148-58. https://doi.org/10.1016/S0029-7844(02)02502-4
  36. Woodward WA, Vinh-Hung V, Ueno NT, et al (2006). Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol, 24, 2910-6. https://doi.org/10.1200/JCO.2005.03.1526
  37. Yoo K-Y, Tajima K, Park S-K, et al (2001). Postmenopausal obesity as a breast cancer risk factor according to estrogen and progesterone receptor status (Japan). Cancer Lett, 167, 57-63. https://doi.org/10.1016/S0304-3835(01)00463-3

Cited by

  1. Breast Cancer in Tunisia: Association of Body Mass Index with Histopathological Aspects of Tumors vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6805
  2. Overweight, Obesity, Oxidative Stress and the Risk of Breast Cancer vol.15, pp.22, 2014, https://doi.org/10.7314/APJCP.2014.15.22.9579
  3. Lack of any Prognostic Value of Body Mass Index for Patients Undergoing Chemoradiotherapy for Esophageal Squamous Cell Carcinoma vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3075
  4. Cancer Notification at a Referral Hospital of Kermanshah, Western Iran (2006-2009) vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.133
  5. Fitting Cure Rate Model to Breast Cancer Data of Cancer Research Center vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7923
  6. Mammographic density and risk of breast cancer by tumor characteristics: a case-control study vol.17, pp.1, 2017, https://doi.org/10.1186/s12885-017-3871-7
  7. Breast Cancer in Young Women: Research Priorities. A Report of the Young Survival Coalition Research Think Tank Meeting vol.4, pp.1, 2015, https://doi.org/10.1089/jayao.2014.0049
  8. Elovl6 is a poor prognostic predictor in breast cancer vol.12, pp.1, 2016, https://doi.org/10.3892/ol.2016.4587
  9. Body mass index and prognosis of breast cancer vol.97, pp.26, 2018, https://doi.org/10.1097/MD.0000000000011220